文献速递白血病

急性髓系白血病RAS突变的基因组与临床全景

Genomic and clinical landscape of RAS mutations in acute myeloid leukemia.
PubMed 文献 · Blood · 2026-10-16

该研究分析了8553例初诊AML患者的集中分子谱数据,其中1775例(21%)携带RAS突变。RAS突变预后受基因组背景和治疗方案影响:在强化疗患者中,NRAS在AML-MR亚组 adverse(HR=1.32),而在NPM1或FLT3-ITD突变者中 favorable;KRAS预示较差OS(HR=1.41)。在维奈克拉为基础的非强化疗患者中,RAS突变在NPM1或IDH1/2突变者中与显著更差的OS相关。

要点

  • RAS突变见于21%初诊AML,NRAS 13%、KRAS 5%、两者共存3%。
  • RAS突变预后依赖基因组背景和治疗方案,不能一概而论。
  • 维奈克拉方案下,RAS突变在NPM1或IDH1/2突变者中预后显著更差。

核心结论

  • RAS突变在AML中常见且预后异质,其影响取决于共突变背景和治疗方式。
  • 研究结果为AML风险分层和RAS靶向策略开发提供了依据。

研究设计与样本

  • 多中心回顾性分析8553例初诊AML患者的集中分子谱数据。
  • RAS突变阳性患者1775例(21%),其中NRAS 1103例(13%)、KRAS 445例(5%)、两者共存227例(3%)。

主要发现

  • RAS突变主要聚集于P-loop热点(G12/G13,70%),NRAS的Q61突变频率高于KRAS(24% vs 9%),KRAS另有K117/A146热点。
  • 23%的患者存在多个RAS突变,RAS信号通路的趋同进化是RAS突变AML的关键特征。
  • RTK/RAS通路突变非均匀富集:PTPN11、KIT和FLT3-TKD突变正相关,CBL突变无关联,FLT3-ITD突变负相关。
  • 强化疗患者多因素分析:NRAS在AML-MR亚组与不良OS相关(HR=1.32,p=0.036),在NPM1突变者(HR=0.61,p=0.036)或FLT3-ITD突变者(HR=0.63,p=0.048)中与较好OS相关;KRAS预示较差OS(HR=1.41,p=0.003)。
  • 非强化疗维奈克拉方案患者中,RAS突变在NPM1突变者(HR=2.98,p=0.007)或IDH1/2突变者(HR=4.06,p<0.001)中与显著更差的OS相关。

临床怎么用

  • AML初诊时应整合RAS突变状态及其共突变背景进行风险分层。
  • 接受维奈克拉为基础方案的患者若携带RAS突变合并NPM1或IDH1/2突变,需警惕预后不良。
  • RAS突变状态可能指导未来RAS靶向治疗策略的开发与患者选择。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RAS mutations are recurrent in acute myeloid leukemia (AML); yet, their genomic and clinical landscape remain poorly characterized. We analyzed centralized molecular profiling data in 8,553 patients with newly diagnosed AML. Of these, 1,775 (21%) harbored RAS mutations: NRAS in 1,103 (13%), KRAS in 445 (5%), and both in 227 (3%). RAS mutations primarily clustered in P-loop hotspots (G12/G13, 70%), with NRAS showing higher Q61 mutation prevalence (24% vs. 9%) and KRAS showing additional K117/A146 hotspots. Multiple RAS mutations occurred in 23% of patients. Convergent evolution of RAS signaling mutations emerged as a key feature of RASmut AML. RTK/RAS pathway mutations were non-uniformly enriched: PTPN11, KIT and FLT3-TKD mutations were positively associated, CBL mutations showed no association, and FLT3-ITD mutations were negatively associated. The prognostic impact of RAS mutations was dependent on the genomic background and treatment. In multivariate analyses in intensively treated patients, NRAS mutations showed opposing associations with overall survival (OS): adverse in patients with AML, myelodysplasia-related (HR=1.32, p=0.036) and favorable in those with NPM1 (HR=0.61, p=0.036) or FLT3-ITD (HR=0.63, p=0.048) mutations, among others. KRAS mutations predicted inferior OS (HR=1.41; p=0.003). In patients treated with non-intensive, venetoclax-based regimens, RAS mutations were associated with markedly inferior OS in patients with NPM1 (HR=2.98, p=0.007) or IDH1/2 mutations (HR=4.06, p<0.001). These data inform risk stratification and development of RAS-targeting strategies in AML.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Rodríguez-Arbolí E, Soria-Saldise E, Barragan E, et al. Genomic and clinical landscape of RAS mutations in acute myeloid leukemia. Blood. 2026. PMID: 42886676. doi:10.1182/blood.2026033409

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。